加载中
BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions. The company is further exploring a specific allogeneic cell therapeutic platform. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. Beyond its therapeutic candidates, BioCardia also provides innovative delivery solutions. These include the Helix biotherapeutic delivery system, engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle, and a line of Morph deflectable guides and sheaths. BioCardia maintains its headquarters in Sunnyvale, California.
前收盘价
US$1.04
−US$0.02 · -1.89%
盘中时间采用ET。市场数据可能有所延迟。
BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions. The company is further exploring a specific allogeneic cell therapeutic platform. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. Beyond its therapeutic candidates, BioCardia also provides innovative delivery solutions. These include the Helix biotherapeutic delivery system, engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle, and a line of Morph deflectable guides and sheaths. BioCardia maintains its headquarters in Sunnyvale, California.
日内区间
当前US$1.04
52周区间
当前US$1.04
盘中时间采用ET。市场数据可能有所延迟。
BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions. The company is further exploring a specific allogeneic cell therapeutic platform. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. Beyond its therapeutic candidates, BioCardia also provides innovative delivery solutions. These include the Helix biotherapeutic delivery system, engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle, and a line of Morph deflectable guides and sheaths. BioCardia maintains its headquarters in Sunnyvale, California.
日内区间
当前US$1.04
52周区间
当前US$1.04
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | 5.8万 USD | 47.7万 USD | 135.2万 USD | 101.5万 USD |
| 销货成本 | 50.5万 USD | 438.7万 USD | 772.6万 USD | 883.4万 USD | 64万 USD |
| 毛利 | −50.5万 USD | −432.9万 USD | −724.9万 USD | −748.2万 USD | 37.5万 USD |
| 研究与开发 | 496.2万 USD | 438.7万 USD | 772.6万 USD | 883.4万 USD | 855.8万 USD |
| 销售、一般及管理费用 | 331.6万 USD | — | — | — | 508.7万 USD |
| 营业费用 | 777.3万 USD | 367.2万 USD | 439.5万 USD | 441.9万 USD | 1300.5万 USD |
| 利息收入 | — | — | — | — | 9000 USD |
| 利息支出 | — | — | — | 6000 USD | — |
| 折旧和摊销 | 50.5万 USD | 6.7万 USD | 8.4万 USD | 8.2万 USD | 6万 USD |
| 营业利润 | −827.8万 USD | −800.1万 USD | −1164.4万 USD | −1190.1万 USD | −1263万 USD |
| 净利润 | −822.8万 USD | −794.6万 USD | −1157.1万 USD | −1190.7万 USD | −1262.1万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
